Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
about
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignanciesDrug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional SignaturesCrucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometryPhase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.The antibodies against 5-bromo-2'-deoxyuridine specifically recognize trifluridine incorporated into DNA.Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumorsDrug-induced Pneumonitis Following the Administration of TAS-102.Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trialA phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.TAS-102, a novel antitumor agent: a review of the mechanism of action.TAS-102: a novel antimetabolite for the 21st century.Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer.Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine.MicroRNA profiles involved in trifluridine resistance.Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy.Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells.Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.DNA replication stress and cancer chemotherapy.Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines.Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer.Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
P2860
Q26777679-1A8B87A1-0A54-4BD8-B88A-DCE3EFF6549AQ28550603-6A62FE37-4B90-472D-B264-70AD2CCE63CCQ34473056-31D20DCA-DE98-4447-8788-9B249056C2C5Q36076767-203859FB-E4BD-4D2E-83BD-F4EBDB0E56B8Q36619557-4083E920-8E0C-4987-9406-F670C135BF6FQ36621566-B07C4734-DB22-400A-AD22-25B0A57C43B8Q36860056-EF46922A-838A-41D1-B6DF-A6FAD1E5E845Q37146675-E16656D2-0262-4C4E-96D7-818F25E71D28Q37383193-EA2F1E24-EE74-422D-9E20-46AA1CF3CD4CQ37588632-A10642E5-D485-47B7-9F89-5E4149D09DADQ37703201-973B1E2A-D7CB-4539-B1EA-4C48EDC0F944Q38597310-9D766435-599B-40F2-B594-370A6385069EQ38652269-F13FD239-34A7-4BDF-A1CC-C2905FFCA864Q38697671-B43346EA-6462-4C69-8105-7D31821BDB5EQ38894690-84084194-4815-4706-87CA-5C02366D0656Q41195691-E316D075-6BB3-4F38-A7C9-9D2D8D21BE6DQ41593018-1EF1A1BD-A838-4701-BA31-CA4E281BF886Q42361962-5B7BA0C5-5ED0-41B8-810C-4EDA7F502202Q42367389-13F0170C-AA78-44C2-B24B-F6318FC265AFQ47145915-84ED3AF3-D787-4057-86AE-8921E02D0553Q47369013-783E00A2-19CD-4FDA-9075-A210BA233640Q48247320-BB4D355D-E0FE-4EE9-96D8-A13144D3E1B5Q48580029-F91AFF7E-CFAE-421D-AE4D-5BE26CD7A21BQ50128950-BB41A028-8CCE-4630-9B02-BD4419982AEFQ55006325-9EAC3F1F-9164-4D92-9B1D-1C9DBFDCD751Q55646151-97868A28-61CB-44AD-B230-509129FC8ACFQ59138354-A73D41C7-A727-4215-817F-389DD64F78F8
P2860
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@ast
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@en
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@nl
type
label
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@ast
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@en
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@nl
prefLabel
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@ast
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@en
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@nl
P2093
P2860
P356
P1433
P1476
Repeated oral dosing of TAS-10 ...... umor activity in mouse models.
@en
P2093
Akiko Osada
Akio Fujioka
Fumio Nakagawa
Hideki Nagase
Hiromi Kazuno
Hiroyuki Okabe
Kazuki Sakamoto
Kei Oguchi
Keiji Ishida
Keisuke Yamamura
P2860
P304
P356
10.3892/OR.2014.3487
P577
2014-09-17T00:00:00Z